| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2021-09-12 |
| タイトル |
|
|
タイトル |
Review ‐ Treatment of Helicobacter pylori Infection 2020 |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
triple therapy |
| キーワード |
|
|
主題 |
bismuth |
| キーワード |
|
|
主題 |
vonoprazan |
| キーワード |
|
|
主題 |
dual therapy |
| キーワード |
|
|
主題 |
sequential therapy |
| キーワード |
|
|
主題 |
hybrid therapy |
| キーワード |
|
|
主題 |
antibiotic resistance |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
O'Connor, Anthony
Furuta, Takahisa
Gisbert, P. Javier
O'Morain, Colm
|
| 書誌情報 |
Helicobacter
巻 25,
号 S1,
p. e12743,
発行日 2020-09-12
|
| 出版者 |
|
|
出版者 |
John Wiley and Sons |
| 権利 |
|
|
権利情報 |
"This is the peer reviewed version of the following article: ""Review‐Treatment of Helicobacter pylori Infection 2020"", Helicobacter; 25(S1): e12743, 2020, which has been published in final form at https://doi.org/10.1111/hel.12743. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited." |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
This review summarizes important studies regarding Helicobacter pylori therapy published from April 2019 to April 2020. The main themes that emerge involve studies assessing antibiotic resistance and there is also growing momentum behind the utility of vonoprazan as an alternative to proton pump inhibitor (PPI) therapy and also bismuth‐based regimens as a first‐line regimen.
Antibiotic resistance is rising wherever it is being assessed and clarithromycin resistance in particular has reached a point where it may no longer be a viable therapy without previous testing in many regions of the world. The evidence for the efficacy of a bismuth‐based quadruple therapy as a firstline therapy is now very clearly established, and there is substantial evidence that it is the best performing first‐line therapy. The utility of vonoprazan as an alternative to PPI therapy, especially in resistant and difficult‐to‐treat groups, has also been considered in great detail this year, and it may offer an opportunity in the near future to reduce the problem of antibiotic resistance. |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1083-4389 |
| EISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1523-5378 |
| PubMed番号 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
32918350 |
| 出版社DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1111/hel.12743 |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
Helicobacter-25-e12743.pdf (289.7 kB)
